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ABSTRACT
Hypophosphatemia leads to rickets and osteomalacia, the latter of which results in decreased biomechanical integrity of bones,
accompanied by poor fracture healing. Impaired phosphate-dependent apoptosis of hypertrophic chondrocytes is the molecular basis
for rickets. However, the underlying pathophysiology of impaired fracture healing has not been characterized previously. To address the
role of phosphate in fracture repair, mice were placed on a phosphate-restricted diet 2 days prior to or 3 days after induction of a mid-
diaphyseal femoral fracture to assess the effects of phosphate deficiency on the initial recruitment of mesenchymal stem cells and their
subsequent differentiation. Histologic and micro-computed tomographic (mCT) analyses demonstrated that both phosphate restriction
models dramatically impaired fracture healing primarily owing to a defect in differentiation along the chondrogenic lineage. Based on
Sox9 and Sox5 mRNA levels, neither the initial recruitment of cells to the callus nor their lineage commitment was effected by
hypophosphatemia. However, differentiation of these cells was impaired in association with impaired bone morphogenetic protein
(BMP) signaling. In vivo ectopic bone-formation assays and in vitro investigations in ST2 stromal cells confirmed that phosphate
restriction leads to BMP-2 resistance. Marrow ablation studies demonstrate that hypophosphatemia has different effects on injury-
induced intramembranous bone formation compared with endochondral bone formation. Thus phosphate plays an important role in
theskeletonthatextendsbeyondmineralizedmatrixformationandgrowthplatematurationandiscriticalforendochondralbonerepair.
 2010 American Society for Bone and Mineral Research.
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Introduction
T
he skeleton is an organ that is subject to constant remodeling
and repair. Fracture initiates a series of molecular and
cellular events that recapitulate embryonic endochondral bone
formation. Upon fracture of long bones, a hematoma is formed,
followedbyaninflammatoryphasecharacterizedbyexpressionof
numerous cytokines. In addition to a periosteal reaction adjacent
to the fracture site, there is recruitment of mesenchymal cells into
theareaofthefracture.Thesecellsthendifferentiateintocartilage
under the influence of bone morphogenetic proteins (BMPs). The
maturing cartilaginous callus is invaded by vasculature and
replaced by bone. Remodeling of the callus leads to restoration of
theanatomicandbiomechanicalpropertiesoftheoriginalskeletal
element.
(1)
A number of factors have been shown to influence fracture
repair, and analyses of the molecular basis for these abnorm-
alities has led to a greater understanding of this process.
(2–7)
Diabetes mellitus leads to impaired fracture healing owing to
premature resorption of the cartilaginous callus.
(6) Prostaglan-
dins also have been shown to play an important role in fracture
repair,
(5) a seminal finding that has led to the avoidance of
nonsteroidal anti-inflammatory medications, which inhibit the
rate-limiting step in prostaglandin production, in patients with
fractures. At 14 days, the calluses of Cox2 null mice exhibit a
decrease in the osseous content, accompanied by a persistence
of mesenchymal cells,
(5) impaired expression of BMP-2 and
BMP-7,
(8,9) and decreased angiogenesis.
(10)
Hypophosphatemia is a feature of several congenital rachitic
disorders.
(11–13) Investigations in murine models of X-linked
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724hypophosphatemia and hereditary vitamin D–resistant rickets
demonstrate that rachitic expansion of the hypertrophic
chondrocyte layer in the growth plate is a consequence of
impaired apoptosis of these cells.
(14) Molecular analyses reveal
that increases in extracellular phosphate activate the mitochon-
drial apoptotic pathway in hypertrophic chondrocytes, a process
that is required for normal endochondral bone formation. Thus,
while phosphate is required for mineralized matrix formation, it
also plays a regulatory role in terminal differentiation of
hypertrophic chondrocytes.
In addition to rickets, congenital and acquired hypopho-
sphatemic states are associated with impaired fracture heal-
ing.
(11–13,15) However, it is unclear what specific role phosphate
plays in this process. These disorders are associated with
osteomalacia owing to impaired matrix mineralization, which
may itself have an important effect on fracture healing.
Furthermore, the hypophosphatemia associated with oncogenic
osteomalacia and X-linked hypophosphatemia is accompanied
by a decrease in 1,25-dihydroxyvitamin D and an increase in
fibroblast growth factor 23 (FGF-23) levels,
(16) which may
contribute to impaired fracture healing. Similarly, impaired
vitamin D action may play a role inthe abnormal fracture healing
observed with vitamin D deficiency. Because neither the cellular
nor the molecular basis for impaired fracture repair in these
conditions has been examined, we undertook investigations to
determine if acute phosphate restriction alters fracture healing
and to identify the mechanism by which hypophosphatemia
leads to impaired skeletal repair.
Materials and Methods
Animal maintenance
Animal studies were approved by an institutional animal care
committee. Male C57Bl/6J (B6) mice were purchased from
Jackson Laboratories (Bar Harbor, ME, USA) and fed standard
chow (Teklad 2018, Madison, WI, USA; 0.65% phosphorus) or a
phosphate-restricted diet (PRD; 0.06% Pi). Under anesthesia, a
closed mid-diaphyseal fracture of the left femur was generated
by controlled blunt trauma using a scaled-down modification of
the apparatus described by Bonnarens and Einhorn.
(17) Ectopic
bone-formation assays were performed under anesthesia by
implanting a Helistat sponge containing 5mg recombinant
human (rh) BMP-2 (a gift from Wyeth, Andover, MA, USA) or
saline, following which the mice were fed the control or
phosphate-restricted diet. Marrow ablation studies
(3) were
performed after 2 days of phosphate restriction in 6-week-old
C57Bl/6J mice. All animals were euthanized by CO2 asphyxiation
prior to harvesting tissue.
Histology
Specimens were fixed, decalcified, and processed for 5mm
paraffin sections and stained with hematoxylin and eosin or
saffranin O and fast green. Histomorphometry was performed
using a Nikon E800 microscope and Osteomeasure software
(Osteometrics, Inc., Atlanta, GA, USA). Proliferation was evaluated
using a Zymed PCNA staining kit (Invitrogen, Carlsbad, CA, USA).
The percent of proliferating cell nuclear antigen (PCNA)-positive
stromal cells 7 days after fracture was determined by evaluating
500 stromal cells on three sections obtained from three fractures
for each condition. Evaluation of nuclear phospho-Smad was
performed using the TSA-biotin kit and anti-phospho-Smad
(Upstate Biotechnology, Lake Placid, NY, USA). In situ hybridiza-
tion was performed using
35S-UTP-labeled antisense riboprobes
as reported previously.
(18,19)
Quantitative micro-computed tomography (mCT)
Scans were performed using a Scanco mCT 40 system (Scanco
Medical, Basserdorf, Switzerland) at 12mm voxel resolution with
200ms integration time under conditions of 55E (KVp) and 145I
(mA). Reference lines were adjusted manually on individual
bones to include the entire callus area. Transverse images were
reconstructed digitally to generate a 3D image of the callus.
Analyses were carried out using Scanco Medical software. A
global threshold algorithm was used to apply a fixed constant
threshold to all specimens. A constrained 3D Gaussian filter
(s¼0.8, filter support¼1 voxel) was used to partially suppress
image noise.
mRNA analyses
The callus was isolated from adjacent tissue, and total RNA was
extracted using Trizol (Invitrogen) and purified on RNeasy
minicolumns (Qiagen, Valencia, CA, USA). Quantitative real-time
polymerase chain reaction (RT-PCR) was performed using
Taqman MGB expression assays (Applied Biosystems, Foster
City, CA, USA) on an ABI 7700 Sequence Detector (Applied
Biosystems). All samples were run in triplicate and normalized to
the average threshold value of triplicate determinations of
b-actin in the same sample. The fold change in mRNA was
normalized to the samples from unfractured control bone
(C57Bl/6J day 0).
Biochemical analyses
Serum phosphate and calcium levels were measured using the
Phosphorus Liqui-UV Kit and Calcium CPC LiquiColor Test Kit
(Stanbio Laboratory, Boerne, TX, USA).
Cell culture and immunocytochemistry
ST2 stromal cells were cultured in Roswell Park Memorial
Institute Media (RPMI) (5.6mM phosphate), 10% fetal bovine
serum (FBS), and 1% penicillin/streptomycin. To evaluate the
effect of hypophosphatemia on BMP-2-induced nuclear phos-
pho-Smad, cells were plated in DMEM (1mM phosphate) 10%
FBS, and 1% penicillin/streptomycin 5 days prior to BMP-2
treatment or kept in basal medium. Twenty-four hours prior to
BMP-2 treatment, 1% heat-inactivated FBS was substituted for
the 10% FBS. Cells were treated with 200ng/mL of BMP-2 for 90
minutes. Immunocytochemistry was performed using anti-
pSmad (Upstate Biotechnology) and detected with a streptavi-
din–Texas red–conjugated goat anti-rabbit antibody (Perkin
Elmer, Waltham, MA, USA). Slides were cover-slipped with 4’,6-
diamidino-phenylindole (DAPI)-containing mounting medium to
permit identification of cell nuclei.
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Membranes were blocked in 5% milk/Tris-buffered saline/
Tween-20 (TBST) (Upstate Biotechnology) and incubated with
anti-pSmad, and immunodetection was performed with an anti-
rabbit horseradish peroxidase (HRP)–conjugated secondary
antibody. Blots were reprobed for actin as a loading control.
Protein expression was visualized using a Western Lightening
Plus-ECL detection kit (Perkin Elmer).
Statistical analysis
For mCT analyses, a two-factor ANOVA using the effects of time,
treatment, and the interaction between time and treatment was
used. A Tukey post hoc least significant difference (LSD) test was
used to identify significant difference between the means. For
RT-PCR analyses, the difference between the mean values of the
mRNA expression and control at each time point was analyzed
by Student’s t test; p<.05 was considered significant.
Results
To determine whether phosphate plays a role in mesenchymal
cell and chondrocyte differentiation during fracture repair, the
effect of a phosphate-restricted diet (PRD) was assessed in a
murine model of fracture healing. In this model, the process of
fracture healing consists of four temporally defined phases of
repair
(1): an early phase characterized by an inflammatory
response with recruitment of mesenchymal cells (days 1 to 4), an
early intermediate phase in which the phenotype associated
with differentiation of these cells into chondrocytes predomi-
nates (days 4 to 10), a late intermediate stage marked by
endochondral resorption and primary bone formation (days 10
to 16), and the final stage in which secondary bone formation
occurs (days 16 to 21).
Mice were placed on the PRD 2 days before induction of a
femoral fracture (PRD–2d) to evaluate whether hypophospha-
temia impairs the recruitment of mesenchymal cells to the
fracture site. A second group of mice was placed on the PRD
3 days after fracture (PRDþ3d) to determine whether hypopho-
sphatemia affects the differentiation of cells recruited to the
callus site. The latter model wasused to circumvent the effects of
hypophosphatemia on the initial inflammatory and mesench-
ymal cell recruitment stages of fracture healing. Biochemical
determinations were performed to evaluate the onset and
degree of hypophosphatemia in this model. As shown in Fig. 1,
the serum phosphate level was significantly decreased at the
time of fracture in the mice subjected to the PRD 2 days prior to
fracture (PRD–2d, day 0).
Initial analysis of callus formation was performed using mCT at
14 and 21 days after fracture, a time when evaluation of callus
size and mineralization is amenable to this technique. 3D mCT
reconstruction revealed that hypophosphatemia decreased the
overall callus size and mineralization in both PRD groups 14 and
21 days after fracture (Fig. 2A). Regardless of dietary regimen,
peak total callus volume was achieved by day 14. Both
phosphate-restriction protocols led to a reduction in total callus
volume and cross-sectional area (see Fig. 2B, C). Mineralized
tissue volume and callus mineral content (see Fig. 2D, E) also
were significantly reduced, whereas a modest decrease in callus
mineral density was observed (see Fig. 2F) in the mice on the
PRD.Areductionintheratioofmineralizedtissuevolumetototal
callus volume was observed in the mice on the PRD (see Fig. 2G).
To examine the effect of phosphate restriction on the
recruitment and differentiation of cells in the callus, histologic
analyses were performed 1 and 2 weeks after fracture. One week
after fracture, the callus of the mice subjected to the PRD either
2 days before or 3 days after fracture was composed largely of
stromal cells, with very little bone or cartilage (Fig. 3). In contrast,
the calluses of mice on the control diet were composed of
stromal cells and cartilage, as well as having a minor osseous
component. At 2 weeks after fracture, all three groups
demonstrated differentiation of cells toward a more mature
phenotype, but the stromal cell compartment remained
strikingly more prominent in the mice on the PRD, accompanied
by a significantly smaller osseous compartment (see Fig. 3).
Quantitative histomorphometric analyses of callus tissue
composition confirmed the predominance of stromal cells in
the callus of both groups of mice on the PRD at 7 days after
fracture (see Fig. 3G). This was accompanied by a marked
reduction in cartilage and bone relative to the callus of mice on
the control diet. By day 14, the control callus exhibited a
significant predominance of bone with a very minor stromal
component. However, at this time point, the bone content of the
calluses of the PRD groups was not significantly different from
that of either their cartilage or stromal components. This
difference in cellular composition largely was responsible for the
decrease in callus volume of the mice on the PRD. Owing to the
presence of a significant amount of matrix in the cartilaginous
compartment, the cellular density of this compartment was one-
third that of the stromal compartment. A smaller contribution to
reduced callus volume was attributable to a modest decrease in
stromal cell proliferation of (4.0 0.5% and 3.7 0.7% PCNA-
positive stromal cells in the PRD–2d and PRDþ3d groups versus
5.4 0.1% in the control calluses, p¼.04).
Fig. 1. Serum mineral ion levels. Calcium and phosphate levels of mice
fed normal chow (control, white bars), mice placed on the PRD 2 days
prior to fracture (PRD–2d, black bars), and mice placed on the PRD 3 days
after fracture (PRDþ3d, gray bars) were measured the day of fracture (d0)
and 1 week after fracture (d7). Data represent the mean and SEM of
samples obtained from 7 to 10 mice for each condition. (
 p<.05 versus
controls.).
726 Journal of Bone and Mineral Research WIGNER ET AL.Fig. 2. mCT analysesof callus formation. A. 3D mCT reconstructed imagesof fracture callusesof mice on thecontrol and PRD diets at 14 days (upper panel)
and 21 days (lower panel) after fracture. Data are representative of images obtained from 5 mice for each experimental condition. Quantitative mCT
analyses of fracture healing 14 and 21 days after: (B) Total callus volume (TV). (C) Average callus cross-sectional area (CsAr). (D) Mineralized tissue volume
(MTV). (E) Callus mineral content (CMC). ( F) Callus mineral density (CMD). (G) Relative mineralized tissue volume (MTV/TV). White bars: Mice fed normal
chow. Black bars: Mice placed on the PRD 2 days prior to fracture (PRD–2d). Gray bars: Mice placed on the PRD 3 days after fracture (PRDþ3d). Data
represent the mean and SD of values obtained from eight representative images of eight independent calluses that were used per treatment group and
per time-point.
 p<.005 versus controls.
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demonstrated prominent areas of cells expressing Sox9 and ColII
in both phosphate-restricted groups. In addition, there was a
decrease in the domain of cells expressing Runx2 and ColX; these
domains colocalized in the callus, implicating the hypertrophic
chondrocytes as the source of Runx2 (Fig. 4A). By day 14 after
fracture, the callus of the mice fed the control diet largely was
composedofColI-expressingcells.Therewasasmallerdomainof
ColX- and ColII-expressing chondrocytes relative to the extensive
ColI domain in the control callus. The domain of Runx2
expression overlapped the ColI- and ColX-expressing domains
(see Fig. 4B).
Whencomparedwiththecontrol callusat14 days, thecalluses
of the mice on the PRD demonstrated a dramatic decrease in
Runx2 expression. This was associated with a decrease in ColX-
and ColI-expressing cells, suggesting that phosphate restriction
impairs differentiation (see Fig. 4B).
Quantitative RT-PCR analyses of early markers of differentia-
tion demonstratedthattheexpressionofSox9 wasunaffected by
phosphate restriction 5 days after fracture and was mildly
decreased 10 daysaftert fracture. Notably, theexpression ofSox5
and ColII, markers of early commitment to the chondrogenic
lineage, also was increased in the phosphate-restricted mice
5 days after fracture. Peak expression levels of aggrecan and
MMP13 were lower in both phosphate-restricted groups
compared with mice fed the control diet (Fig. 5A). In addition,
the phosphate-restricted mice failed to show the increase in
osteocalcin mRNA expression observed in the control mice at
14 days after fracture. To define the molecular basis for impaired
differentiation of cells committed to the chondrocyte lineage,
the expression of transcription factors that play a key role in
endochondral bone formation was examined. As demonstrated
in Fig. 5A, the expression of Runx3, Runx2, and osterix was
unaffected bythedietaryregimen5daysafterfracture.However,
by 10 days after fracture, there was a dramatic increase in the
expression of Runx3 in the control callus, whereas expression of
this transcription factor in the calluses of the mice on the PRD
was not significantly increased. At 14 days after fracture, the PRD
calluses failed to show the marked enhancement in the
expression of Runx2 and osterix mRNA observed in the control
callus (see Fig. 5A).
Since these three transcription factors are induced by
BMPs,
(20–22) investigations were undertaken to determine if
BMP signaling was impaired in the calluses of the mice on the
PRD. The expression of BMP2 and BMP4 was not significantly
altered by phosphate restriction at 5 and 10 days after fracture
(see Fig. 5B). Expression of BMPRIA, BMPRIB, and BMPRII was
Fig. 3. Callus histology and histomorphometry. Representative sections of callus formation 7 (upper panels) and 14 (lower panels) days after fracture in
mice fed the control diet (A, D) or the phosphate-restricted diet 2 days before (B, E) or 3 days after (C, F) fracture. Cartilage stains red with saffranin O and
stromal cells stain pink, whereas bone stains green with fast green. (G) Histomorphometry. Percentages of the callus area occupied by stromal cells,
cartilage,andboneareindicated.Datarepresentthemeanvalueobtainedfromanalysesoffiverepresentativesectionsfromeachoffourcallusespertime
point. Significant differences (p<.05) are present between the experiental and control groups, with the exception of cartilage content at day 14.
Fig. 4. Insituhybridizationanalyses.Sectionsfromthecallusesofcontrol
mice and mice on the PRD were subjected to in situ hybridization
analyses for the mRNAs indicated on the right. Data in A were obtained
7 days after fracture, whereas those in B was obtained 14 days after
fracture. The upper part of each image represents half of the callus, with
the original cortical bone on the lower aspect. Data represent those
obtained from two sections from each of three mice for each time point
and dietary condition.
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mice 5 days after fracture. This was accompanied by a marked
reduction in the presence of nuclear pSmad-positive cells in the
stromal and cartilaginous components of the fracture callus of
the phosphate-restricted mice relative to that of the control
mice, suggesting impaired BMP action (Fig. 6B, C versus 6A).
To confirm that activation of Smad1 is impaired by low
phosphate in stromal cells, ST2 cells were maintained in RPMI/
Fig. 5. Quantitative RT-PCR analysis (A) Expression of mRNAs encoding markers and transcriptional regulators of chondrogenic and osteogenic
differentiation was compared with that obtained from the adjacent unfractured bone. (B) Expression of mRNAs encoding BMP-2 and -4 and their
receptors was compared with that obtained from the adjacent unfractured bone. mRNA levels from three calluses were compared with those from
unfractured bones ofmice fed thesame diets.All dataare normalized to b-actin levels in the samesample andpresentedas thefold changein expression
relative to unfractured bone (d0). Data represents the mean   S.D.
Fig. 6. PhosphaterestrictionattenuatesnuclearlocalizationofpSmad1.(A)Controlcallus.MoststromalcellsarepositivefornuclearpSmad1(brownstain);
asteriskindicatesa blood vessel with no nuclear pSmadin endothelialcells. (B, C) Callusesof mice placed on the PRD 2 days before or 3 days after fracture.
Arrows point to the rare cells with nuclear pSmad1. Insets in the right upper corner represent chondrocytes from the same calluses. (D–H) ST2 cells were
culturedinRPMI(5.6mMphosphate;D,E)orDMEM(1mMphosphate;F,G).ImmunocytochemistryforpSmadwasperformed90minutesafterrhBMP-2(D,
F). DAPI staining was performedto permit identification of nuclei (E, G). (H) Phosphate restriction attenuates Smad phosphorylation. Cells were cultured as
earlier, and lysates were subjected to Western blot analyses for pSmad (arrow). Data are representative of those obtained in three independent
experiments.
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BMP-2 treatment, nuclear pSmad signals predominated in the
cells cultured in RPMI, which contains 5.6mM phosphate, and
were rare in the cells cultured in DMEM (see Fig. 6F), which
contains 1mM phosphate. Western blot analyses demonstrate
impairedSmadphosphorylationinresponsetoBMP-2inthecells
cultured in DMEM (see Fig. 6H).
To confirm that hypophosphatemia impairs BMP action in
vivo, ectopic bone-formation assays (BFAs) were performed by
implanting BMP-2-impregnated Helistat sponges subcuta-
neously into C57Bl/6J mice, which then were placed on the
PRD or control diet. Six days after BFA, there was little invasion of
cellsintothespongeineithergroupofmice(Fig.7A,B).However,
by 9 days after BFA, the sponges in the mice on the control
diet exhibited a high degree of cellularity, with evidence of
mesenchymal cell differentiation into chondrocytes (see Fig. 7C,
E). In contrast, in the mice fed the PRD, there was marked
hypocellularity, with cells occupying only the rim of the sponge
(see Fig. 7D, F). By 14 days, when the sponges in the control mice
were replaced by bone and a marrow cavity, the sponges from
the mice subjected to the PRD showed no further increase in
cellularity (see Fig. 7G, H).
Both the ectopic BFA and long bone fractures recapitulate
embryonic endochondral bone formation. In order to address
whether hypophosphatemia impairs intramembranous bone
formation as well, marrow ablation studies (a model of injury-
induced bone repair after surgical reaming) were performed in
miceplacedonthePRD2dayspriortotheprocedure.Phosphate
Fig. 7. Phosphate restriction impairs rhBMP-2-induced ectopic bone formation. BFAs were performed in mice fed chow (A, C, E, G) or the PRD (B, D, F, H)
afterimplantationofarhBMP-2-impregnatedHelistatsponge.Histologywasevaluated6(A,B),9(C.D;high-powerE&F),and14(G)daysafterimplantation.
Sections are representative of those obtained in five independent experiments for each time point.
730 Journal of Bone and Mineral Research WIGNER ET AL.restriction did not impair the stromal cell response either at 5 or
9 days after marrow ablation (Fig. 8B, F) compared with that
observed in mice on the control diet (see Fig. 8A, E). Based on in
situ hybridization for osteocalcin expression, differentiation of
these cells into osteoblasts was not adversely affected by
phosphate restriction (Fig. 8D, H versus 8C, G).
Discussion
The skeletal abnormalities seen in hypophosphatemic disorders
highlight the importance of phosphate in growth plate
maturation and skeletal mineralization.
(14,23–25) However, little
is known about the role of phosphate in skeletal development
and repair. The current investigations identify a critical role for
phosphateinfracturerepairandimplicatearoleforphosphatein
normal skeletal development and responsiveness to BMPs.
The BMPs belong to the transforming growth factor b
superfamily of growth factors. When implanted subcutaneously,
BMP-2 leads to ectopic bone formation by a series of events that
recapitulate embryonic endochondral bone formation.
(26)
Furthermore, BMPs have been used to promote healing of
fractures, including those that exhibit nonunion, a pathologic
condition associated with failure of fracture healing.
(27–30) BMPs
also have been shown to have critical roles in the development
of other organ systems.
(31,32) as well as in limb patterning.
(33)
Misexpression of the BMP inhibitor noggin in chick limb buds
prevents both mesenchymal condensation and chondrogenic
differentiation of these mesenchymal cells.
(34,35) Although BMP2,
BMP4, and BMP7 are expressed throughout limb development,
their functions are not completely redundant. In the absence of
BMP2 and BMP4, chondrogenesis proceeds normally, with the
exception of a delay in hypertrophic differentiation, but
osteogenesis is markedly impaired.
(33) Absence of BMP14 delays
Fig. 8. Intramembranous bone formation. Marrow ablation was performed on mice fed a control diet (A, C, E, G) or phosphate-restricted diet 2 days prior
to the procedure (B, D, F, H). Stromal cell response and differentiation were evaluated 5 (A, B, C, D) and 9 days after marrow ablation (E, F, G, H). In situ
hybridization for osteocalcin mRNA (C, D, G, H) was performed to evaluate stromal cell differentiation.
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(36) whereas ablation of BMP4 hasno effect.
(37) In
contrast, mice lacking BMP2 in their limbs exhibit a decrease in
bone mineral density, develop spontaneous fractures, and
display markedly impaired fracture healing.
(38) The dramatic
fracture phenotype observed in these mice, despite normal
levels of BMP4 and BMP7 mRNA, suggests that BMP2 is
specifically required for the earliest stages of fracture repair.
Absence of BMP2 may impair the inflammatory response to
fractureor,alternatively,depletethepool(orimpairthefunction)
of precursor cells that are normally recruited to the fracture site
during the inflammatory phase. The latter explanation would be
most consistent with our investigations in the hypopho-
sphatemic fracture model: The acute nature of the phosphate
restriction in these studies is unlikely to affect the pool of
precursor cells significantly.
The most striking pathologic abnormality in the hypopho-
sphatemic calluses is the marked impairment in progression of
chondrogenic differentiation of the mesenchymal cells that are
recruited to the fracture callus, analogous to that observed with
postnatal impairment of BMP2 signaling.
(39) The recruitment of
mesenchymal cells, which occurs during the initial inflammatory
phase of fracture repair, is thought to depend on growth factors,
cytokines, and prostaglandins, but studies in the BMP2 null mice
demonstrate a role for this growth factor in this process. Despite
theBMP2resistanceweobserved,andincontrasttomicelacking
BMP2 in their limbs, the recruitment of cells during the
inflammatory phase of fracture repair was not profoundly
impaired by hypophosphatemia. This suggests that the duration
or degree of impaired BMP2 function is an important
determinant of this phase of fracture repair. Regardless of
whether the mice are normophosphatemic (PRDþ3) or
hypophosphatemic (PRD–2) at the time of fracture, the
molecular and histologic phenotype of the fracture callus is
the same. This suggests that the recruitment of mesenchymal
cells to the fracture site and commitment to the chondrogenic
lineage are not affected by hypophosphatemia because the
PRD–2d mice are hypophosphatemic during these stages,
whereas the PRDþ3d mice are not. However, the subsequent
differentiation of these cells is severely impaired. This impaired
differentiation leads to a decrease in callus volume primarily
owing to the fact that there is a marked reduction in
chondrocytes and osteoblasts resulting in an increase in cell
density owing to the presence of less matrix. A minor reduction
in stromal cell proliferation also contributes to the decrease in
callus size. The reduction in callus matrix is also likely to be
responsible for the reduction in mineralized tissue volume (MTV/
TV) observed. Interestingly, despite the presence of hypopho-
sphatemia, the density of the mineral that is present in the callus
(CMD) is only mildly reduced.
Because of the effects of BMP-2 on stromal cell differentiation
and the essential requirement of this growth factor for fracture
repair, we examined the effects of low phosphate on BMP2
signaling in the callus, in cultured stromal cells, and in ectopic
BFAs. The impaired Smad phosphorylation observed in vivo and
in vitro in the stromal cells and striking paucity of mesenchymal
cell invasion observed in the ectopic BFAs performed in
hypophosphatemic mice demonstrate that BMP2 signaling in
these cells is impaired under low-phosphate conditions both in
vitro and in vivo. Similarly, there was a dramatic decrease in the
presence of pSmad-positive chondrocytes in the calluses of the
mice on the PRD. Whether this effect of phosphate restriction on
BMP2 signaling is limited to cells involved in endochondral bone
formation is currently unknown. Investigations in HaCaT (human
keratinocyte) cells and in HeLa cells (from a human cervical
cancer) demonstrate rigorous Smad phosphorylation in
response to BMPs despite the fact that they are cultured in
DMEM (1mM phosphate), providing the rationale for choice of
thisculturemediuminourstudies.
(40,41)Similarly,primarybovine
articular chondrocytes cultured in DMEM/F12 (1mM phosphate)
demonstrate nuclear pSmad in response to BMP treatment.
(42)
Interestingly, the observation that hypophosphatemia does not
significantly alter the differentiation of stromal cells in the
marrow ablation studies, which recapitulate intramembranous
bone formation, suggests that the actions of BMPs are not
essential in this model or that the stromal cell population that
reconstitutes bone inthis model differsfrom that recruited in the
fracture model and ectopic bone formation assays, which
recapitulate endochondral bone formation. Notable in this
respect is the observation that periosteal injuries heal by
endochondral bone formation, whereas the endosteal injuries
heal by intramembranous bone formation.
(43)
The results of the ectopic BFAs and investigations in ST2 cells,
combined with those of the fracture studies, suggest that
inflammation-mediated cell recruitment is BMP-independent.
However,BMP-2mayberequiredtosustainthepoolofprecursor
cells that are recruited to the fracture site or to maintain their
functional activity. The initiation of hypophosphatemia just prior
to or after the fracture in our model would circumvent this
potential impairment of BMP2 action on progenitor cells, thus
leading to a less severe phenotype than that observed in the
mice where BMP2 is ablated from the limbs during embryonic
development. Nonetheless, our data point to a critical role for
phosphate in fracture healing and endochondral bone repair.
They also suggest that BMP resistance has a pathophysiologic
role in the etiology of the impaired fracture repair observed in
hypophosphatemic states.
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